The project will focus its activities on three priority virus groups, responsible of major human viral diseases for which the development of drugs is considered essential: flaviviridae (Dengue), picornaviridae (enterovirus 71) and paramyxoviridae (RCV and hMPV). On the other hand, exploratory researches will be performed on other virus families that have the potential to cause epidemics, like the arenaviruses group, alphaviruses, bunyaviruses, coronaviruses and noroviruses .
The SILVER project contains 6 work packages.
SILVER WP4 will centralize and coordinate (i) ADME- (absorption, distribution, metabolism, and excretion)-tox studies with those compounds that exert the most potent and selective in vitro activity (ii) establish appropriate formulations of these compounds for testing in animal models and (iii) evaluate the potential protective activity in relevant animal models. WP4 aims to
- Determine ADME-tox profile (Task 4.1) before deciding to study the potential protective effect of novel compounds in an infection model in animals.
- Establish suitable formulation(s) for administration to animals (Task 4.1).
- Establish and optimize entero- and flavivirus mouse and/or monkey models for evaluation of novel antiviral strategies (Task 4.2).
- Assess the efficacy of selected molecules [compounds with potent in vitro antiviral activity and no major liabilities in terms of ADME-tox] in relevant small animal models (mice, hamsters, cotton rats, ferrets) (Task 4.3).
- Study the protective activity of molecules [with demonstrated outstanding safety and excellent antiviral activity in small animal models (see Task 4.3)] in macaque models (Task 4.4).